| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The development of optimal dosage of anti-microbial agents based on pharmacokinetics/pharmacodynamics (PK/PD) is an urgent issue. This study was acquired and analyzed PK data in patients with special pathological conditions (hemodiafiltration (HDF), meningitis, systemic inflammatory response syndrome (SIRS)). We revealed meropenem and cefazolin PK in patients with HDF, ceftazidime, cefepime, vancomycin and linezolid PK in patients of meningitis, and daptomycin PK in patients of SIRS, and then developed effective and safe dosing regimens for individual patients. The findings are immediately available for clinical setting and really helpful for proper use of anti-microbial agents.
|
